Liver and intrahepatic bile duct neoplasm

Researchers at Oslo University Hospital are testing whether a liver transplant can help people with perihilar cholangiocarcinoma, a bile duct cancer that cannot be removed with standard surgery. The trial enrolls about 15 participants who have no signs of cancer spread beyond the…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

Researchers are testing a new targeted radioligand therapy called [225Ac]Ac-FL-261 in people with advanced solid tumors that overexpress a protein called c-MET. The therapy pairs a radioactive particle with a molecule that seeks out c-MET, aiming to deliver radiation directly to …

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

Researchers are testing an experimental oral drug called XNW29016 in adults with advanced solid tumors that have not responded to standard treatment. The trial has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look at early signs of activity…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This early-stage trial tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study includes 38 adults with advanced solid tumors, such as liver cancer, who have not responde…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This study tests a new drug (CDX-1140) combined with three other cancer drugs for people with advanced biliary tract cancer that has spread or come back after treatment. About 60 adults will receive the drugs through an IV and a pill over 21-day cycles for up to 2 years. The goal…

This study tests a combination of three drugs (atezolizumab, bevacizumab, and memantine) in 19 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be newly diagnose…

This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control t…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This study tests whether taking prednisone, a steroid, before and during radiation therapy can protect the liver in people with liver cancer. About 20 participants will take prednisone for a short time around their radiation sessions. The goal is to see if it reduces liver inflam…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase II trial tests a combination of immunotherapy (tislelizumab), chemotherapy (gemcitabine plus cisplatin or oxaliplatin), and targeted radiation before possible surgery in 38 people with hilar cholangiocarcinoma that is borderline or not removable. The goal is to see if …

This phase 2 trial is testing whether combining an experimental immunotherapy (MK-2010) with an antibody-drug conjugate (sacituzumab tirumotecan) can help people with advanced solid tumors. The goal is to see if the combination is safe and can shrink or eliminate tumors. Particip…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

Researchers are running a Phase I trial of BA1203, an experimental drug given intravenously every two weeks, in adults with advanced solid tumors that have worsened after standard treatments. The study aims to find out whether BA1203 is safe and tolerable, how the body processes …

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, …

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see i…

Researchers are running a first-in-human Phase I trial of AK157D1, an experimental drug given by intravenous infusion, in adults with advanced solid tumors that have worsened after standard treatment or have no standard options left. The study aims to find out whether the drug is…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This study tests an experimental drug called BL-M08D1 in adults with advanced or metastatic digestive tract tumors and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors and slows disease progression. Participants receive the drug by intraven…

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

Researchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

Researchers are running a first-in-human Phase 1 trial of BA1106, an experimental intravenous drug, in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and tolerability, and to see how the body processes the drug. Pa…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

Researchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …

Researchers are testing whether adding radiotherapy to a few growing liver cancer spots while continuing first-line systemic therapy helps people live longer without their cancer getting worse, compared with switching to second-line drugs right away. The trial enrolls adults with…

This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…

Researchers are running a first-in-human Phase 1 trial of BA1301, an experimental drug given intravenously every three weeks, in adults with advanced solid tumors that cannot be removed by surgery. The trial enrolls about 70 people aged 18 to 75 whose cancer has progressed after …

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

Researchers are testing an experimental antibody injection called MHB118C in adults with advanced solid tumors that have not responded to standard treatments. The trial aims to find out whether the drug is safe, what side effects it causes, and what dose people can tolerate. Part…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

Researchers are testing whether a combination of retlirafusp alfa, famitinib, and liver-directed chemotherapy can shrink locally advanced intrahepatic cholangiocarcinoma enough to allow surgery. Adults with tumors that are technically removable but difficult to operate on directl…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This study tests histotripsy, a non-invasive treatment that uses focused ultrasound to destroy liver tumors without needles or surgery. It involves 40 adults with liver cancer who cannot have surgery or other standard treatments. The goal is to see if it is safe and effective at …

Researchers are testing whether removing liver tumors surgically and then giving two drugs, camrelizumab and apatinib, helps people with advanced hepatocellular carcinoma that has spread to other organs. The trial enrolls adults with liver cancer that has spread to places like ly…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

Researchers are testing whether a specialized radiation technique called lattice radiotherapy, combined with PD-1/PD-L1 inhibitor drugs, can safely shrink large tumors in people with advanced solid cancers. The trial enrolls adults whose cancer has progressed after standard treat…

This study tests whether taking atorvastatin (Lipitor) daily for 48 weeks can reduce the risk of liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants are randomly assigned to receive either the drug or a placebo. The main goal is to see if atorvastati…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) before and after surgery can improve outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. The trial will enroll 24 adul…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

Researchers are testing whether combining sacituzumab tirumotecan and pembrolizumab can shrink tumors or slow disease progression in people with advanced biliary tract cancer that has worsened after initial treatment. The trial enrolls 38 adults with unresectable, recurrent, or m…

Researchers are testing an experimental oral drug called T-1301 in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The Phase I trial aims to find the highest dose participants can tolerate and the dose best suited for later studies. A…

This early-stage trial is testing a new drug called ZW251 in about 100 people with advanced solid tumors, including liver cancer (hepatocellular carcinoma), a type of lung cancer (squamous cell non-small cell lung cancer), and germ cell tumors. ZW251 is an antibody-drug conjugate…

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…

This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…

This study tests a new approach for people with advanced liver cancer that cannot be surgically removed. Participants receive radiation followed by an injection of their own specially trained immune cells (dendritic cells), a pneumonia vaccine to boost immunity, and immunotherapy…

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, for people with liver cancer (hepatocellular carcinoma) in Korea. About 246 patients who are already eligible for these drugs under Korean guidelines will be observed in real-world settings. The go…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

Researchers are testing an experimental intravenous drug called T-1201 in adults with advanced solid tumors that have not responded to standard therapy or have no standard treatment left. The main goals are to find the highest dose people can tolerate and the dose best suited for…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

Researchers are testing whether adding the immunotherapy drug ivonescimab to standard GEMOX chemotherapy can shrink biliary tract tumors enough to allow surgery. The trial enrolls 87 adults with locally advanced biliary tract cancer, including cancers of the bile ducts and gallbl…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

Researchers are testing an experimental oral drug called GH56 in people with advanced solid tumors that have lost the MTAP gene. The trial enrolls adults and adolescents whose cancer has progressed after standard treatment or who have no standard options left. The study first fin…

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…

Researchers are testing whether adding photon radiotherapy to the standard immunotherapy combination of atezolizumab and bevacizumab can improve outcomes for people with unresectable hepatocellular carcinoma. The trial enrolls 45 adults whose liver cancer cannot be removed by sur…

This phase 3 trial tests whether adding a surgical glue called N-butyl-2-cyanoacrylate to standard pancreatic surgery can prevent postoperative pancreatic fistula—a common and serious leak of digestive fluids. About 194 patients with soft pancreas tissue undergoing tumor removal …

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

Researchers are testing whether adding photon radiotherapy to two immunotherapy drugs, tremelimumab and durvalumab, helps people with hepatocellular carcinoma that cannot be removed by surgery. The trial enrolls about 45 adults with BCLC stage B or C liver cancer. Participants re…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

Researchers are testing a new oral drug called HTL0039732 in people with advanced solid tumors that have not responded to standard treatments. The trial gives the drug alone and in combination with atezolizumab or other approved cancer therapies. The main goals are to find a safe…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This phase 2 trial tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs, tremelimumab and durvalumab. The goal is to see if this approach is safe and works bett…

Researchers are exploring whether giving different combinations of systemic drugs, with or without local interventional therapy, can help people with advanced hepatocellular carcinoma whose disease has worsened after first-line targeted and immune therapy. The study enrolls about…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…

Researchers are testing whether injecting an oncolytic virus called H101 directly into tumors, followed by immune checkpoint inhibitor drugs, is safe and can shrink metastatic colorectal, gastric, or liver cancers that have worsened after multiple prior treatments. About 30 adult…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This study looks at whether delivering chemotherapy directly into the liver through a small implanted pump can help people with pancreatic or duodenal adenocarcinoma that has spread to the liver after surgery and standard chemotherapy. Participants receive floxuridine through the…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to se…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. …

This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if…

This study tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard two-drug combos for people with advanced liver cancer that cannot be removed by surgery. About 590 adults who have not had prior cancer treatment will participate. The …

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

Researchers are testing a combination treatment for people with intrahepatic cholangiocarcinoma, a cancer of the bile ducts inside the liver that cannot be removed by surgery. The approach delivers high-dose chemotherapy directly into the liver's blood supply (HAIC-FOLFOX) and ad…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

Researchers are running a Phase 1 trial of IBI3001, an intravenous drug, in adults with unresectable, locally advanced or metastatic solid tumors. The study aims to find the highest dose people can tolerate and the dose to use in later trials. Participants receive IBI3001 by infu…

Researchers are testing an experimental drug called IBI3020 in adults with solid tumors that have spread or cannot be removed by surgery. IBI3020 is an antibody-drug conjugate that targets the CEACAM5 protein on tumor cells and delivers two different payloads. The main goals are …

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract can…

This phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

Researchers are collecting data on how well microwave ablation works for people with primary or secondary liver tumors and small kidney tumors that surgery cannot remove. The procedure uses heat to destroy tumors. The study follows participants' normal care and tracks tumor recur…

This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study…

Researchers are testing an experimental mRNA injection called ABO2011 in adults with advanced solid tumors that have worsened after standard treatment. The injection delivers genetic instructions for interleukin-12, a protein that can stir up an immune response, directly into the…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase II trial is testing a combination of two chemotherapy drugs—trifluridine/tipiracil (pills) and oxaliplatin (IV)—in people with advanced or metastatic biliary tract cancer whose first treatment stopped working. The goal is to see if this combo can control the cancer bet…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This early-stage trial tests an investigational drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular carcinoma) or a type of lung cancer (squamous-cell non-small cell lung cancer). Some participants receive ABBV-324 alone, while others get a standard drug ca…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

Researchers are testing whether adding the immunotherapy drug sintilimab to one of two chemotherapy regimens helps people with metastatic biliary tract cancer who have not received prior treatment. About 54 participants will be randomly assigned to receive sintilimab plus either …

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…

Researchers test whether irreversible electroporation, a technique that uses electrical pulses to destroy tumor cells while sparing nearby blood vessels and bile ducts, can boost the effects of lenvatinib and sintilimab in people with advanced hepatocellular carcinoma that cannot…

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Researchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…

Researchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study looks at whether adding radiation to the liver can improve outcomes for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that has spread. About 60 adults with at least one liver tumor 3 cm or larger will receive either standard therapy a…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study tests whether adding a non-invasive sound wave treatment (histotripsy) to standard chemotherapy can help people with advanced colorectal cancer that has spread to the liver. About 100 adults whose cancer cannot be removed by surgery will receive both treatments. The go…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…

Researchers are testing a new device that uses endoscopic ultrasound to guide microwave energy directly into pancreatic and liver tumors that cannot be removed by surgery. The study enrolls 75 adults with locally advanced or metastatic cancer. The main goal is to see whether the …

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase trial tests whether injecting a medical glue (Histoacryl®) into the pancreas during Whipple surgery can strengthen the connection between the pancreas and intestine and prevent dangerous leaks. The study involves 30 patients with soft pancreases and narrow ducts,…

This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This trial tests two chemotherapy strategies for people who have had surgery for malignant biliary tract tumors. One group receives hepatic arterial infusion chemotherapy, where drugs are delivered directly to the liver through a catheter. The other group takes capecitabine pills…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

Researchers are testing whether adding oral fecal microbiota transplantation capsules can help control advanced hepatocellular carcinoma that has worsened during treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The trial enrolls 30 adults with liver can…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare …

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the …

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This phase II trial tests whether combining anlotinib, benmelstobart, and hepatic arterial infusion chemotherapy (HAIC) can shrink tumors in people with unresectable hepatocellular carcinoma, the most common type of liver cancer. The study enrolls adults aged 18 to 75 with confir…

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two yea…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests whether combining an immunotherapy drug (iparomlimab/tuvonralimab), targeted radiation, and the drug lenvatinib can improve outcomes for people with intermediate-stage liver cancer that may be removable by surgery. Participants receive the combination bef…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study aims to improve how doctors see liver damage (cirrhosis), liver cancer, and high blood pressure in the liver using a special PET/MRI scan. About 45 adults with cirrhosis will get this scan to see if it gives clearer pictures than current methods. The goal is to make di…

Researchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…

Researchers are building and testing an AI model that combines digital pathology slides and MRI radiomics to predict how well advanced hepatocellular carcinoma responds to systemic therapy. The study enrolls 280 adults with HCC who have received systemic treatment and have leftov…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

Researchers are testing a non-invasive finger-press test called InstaSure to see if it can detect hepatocellular carcinoma, the most common form of liver cancer. The study enrolls 40 people: 30 with liver cancer, 5 with benign liver disease, and 5 healthy controls. A fingertip pr…

Researchers test whether a special MRI scan, hyperpolarized 13C pyruvate, can predict how well liver cancer responds to radiotherapy combined with atezolizumab and bevacizumab. The trial enrolls 45 patients with hepatocellular carcinoma who cannot have surgery. Participants recei…

Researchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The …

Researchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. Th…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…

Researchers at Tongji Hospital are testing whether adding two specialized MRI sequences to routine liver scans can reveal the immune microenvironment of liver cancer. The study plans to enroll 400 adults with confirmed or suspected hepatocellular carcinoma who are scheduled for s…

Proton therapy sends radiation into tumors, and researchers want to see exactly where that dose lands. This study tests radioacoustic imaging, which uses ultrasound sensors on the belly to pick up faint sound signals that proton radiation makes inside the body. The team will work…

This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…

Researchers are testing whether a blood test that measures sugar chains on proteins can predict which liver transplant patients will lose their new organ or die within a year. The study enrolls 600 adults who are waiting for or have received a liver transplant. By analyzing blood…

Researchers are building a computer model that combines detailed features from preoperative MRI scans with routine clinical information to estimate the risk of cancer returning after surgery for colorectal liver metastases. The study includes adults who had surgery for these live…

Researchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…

Researchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked. Researchers will compare the new CEUS criteria with standard CT or MRI scans in 200 adults. If accurate, this could make follow-up safer and easier by avoidin…

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

This study is testing a new, single-use scope called the Dragonfly™ Digital Pancreaticobiliary System. It is designed to help doctors see inside the bile and pancreatic ducts during an endoscopy. The study will enroll up to 75 adults with bile duct stones or narrowings (stricture…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Bile leakage is a serious complication after liver resection in children and can require more procedures or repeat surgery. This trial enrolls 12 children and adolescents up to age 18 who are having liver resection and are at high risk of bile leakage because their tumors sit nea…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

Liver cancer often returns after surgery, and researchers want to know if immune checkpoint inhibitors can lower that risk. This real-world study follows people who had curative liver surgery for hepatocellular carcinoma and are at high risk of recurrence. Some receive adjuvant i…

Many people with advanced cancer take opioid pain medicines, which often cause constipation. This trial compares two laxatives, macrogol/electrolytes and magnesium hydroxide, to see which works better at preventing constipation when opioids are started. Adults with advanced cance…

Researchers at the University of Hong Kong are testing a new way to choose adjuvant therapy for people with hepatocellular carcinoma (HCC) who have a higher risk of the cancer returning after liver resection or ablation. During surgery, they collect a patient's liver and tumour t…

Researchers are testing whether an implanted chemo pump can prevent bile duct cancer from coming back in the liver after surgery. Adults with intrahepatic cholangiocarcinoma that can be removed by surgery receive the pump, which delivers floxuridine directly to the liver over fou…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

Researchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

Researchers are comparing two music-based programs to see which may better reduce anxiety in people with advanced cancer. One program pairs participants with a music therapist who uses an AI-powered platform to write songs together. The other has trained staff guide participants …

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

Researchers at Massachusetts General Hospital are testing HARMONY, a psychoeducational program for people recently diagnosed with hepatocellular carcinoma, the most common form of liver cancer. The study enrolls about 50 adults who received their diagnosis within the past six mon…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

Researchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, …

This Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over ti…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This pilot study tests a spiritual care program called PEACE, led by chaplains and clinicians, for people with advanced cancer. The goal is to see if it helps patients whose faith influences their medical decisions. Sixty participants will receive two counseling sessions or usual…

This study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and …

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This phase II trial tests whether a standardized acupuncture protocol can reduce peripheral neuropathy, a common and often lasting side effect of oxaliplatin chemotherapy. Participants are adults with gastrointestinal solid tumors who stopped oxaliplatin-based treatment and still…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This pilot study aims to develop new ways to diagnose colon cancer and predict if it will spread to the liver. Researchers will collect blood and liver tissue samples from 51 patients undergoing surgery for colon cancer or benign colon growths. The goal is to find biomarkers that…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study looks at how cancer and its treatments change a person's sense of taste and smell, and how that affects their eating and nutrition. Researchers will follow 306 people newly diagnosed with cancer of the mouth, throat, colon, or liver. They will use questionnaires, taste…

This study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …

This study looks at a method called 'Teaching the Teachers' to help spread liver cancer diagnosis guidelines. Experts learn the guidelines first, then teach other radiologists around the world. The goal is to see if this approach increases how often the guidelines are used. About…

Researchers are studying 300 adults with hepatocellular carcinoma, the most common form of liver cancer, who receive photon or proton radiotherapy. The trial measures immune responses and radiation dose parameters to see whether they predict how long patients live without their c…

Researchers are collecting weekly urine samples from adults with solid tumor cancers to look for metabolic changes that occur as death approaches. The study aims to understand the biology of dying and explore whether a test could one day predict the last days or weeks of life. Be…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study is observing 200 adults with advanced liver cancer who are starting a new treatment with two drugs, tremelimumab and durvalumab. Researchers want to see how long it takes for liver problems to get worse, how patients feel, and how safe the treatment is in everyday medi…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is collecting information from up to 40,000 cancer patients who are receiving radiation therapy. Researchers will track their outcomes to better understand what works and how to reduce side effects. The goal is to improve patient care by learning from real-world treatm…

This study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their v…

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

Researchers are studying whether certain molecules in tumor tissue or blood can predict how well liver cancer treatment works and who is likely to relapse. The study follows about 500 adults with hepatocellular carcinoma who receive standard care, such as surgery, ablation, targe…

This study looks at the genes in cancer tumors to find mutations that might be important for how the cancer grows. Researchers will use leftover tissue from surgeries or biopsies, along with a blood or saliva sample, to compare cancer genes to normal genes. The goal is to underst…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

Researchers are studying whether body mass index (BMI) is linked to health-related quality of life in people with solid tumors. The trial includes about 1,380 adults with a confirmed solid tumor diagnosis. Participants complete standard quality-of-life questionnaires, and researc…

This study creates miniature, lab-grown versions of liver cancer tumors from patient biopsies. Researchers will test how well different treatments work on these models and look at how gut health and the tumor's environment affect the disease. The goal is to better understand live…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study tests a new imaging method called qDSA that measures blood flow in real time during liver embolization, a procedure that blocks blood supply to tumors. Up to 20 participants will have qDSA and ultrasound images taken before, during, and after the procedure. The goal is…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

This study looks at whether a thorough health assessment before liver surgery can help older patients (70+) have fewer serious complications and recover better. Researchers will give 242 participants a special geriatric evaluation that checks frailty, memory, nutrition, and daily…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…